China Medical University Hospital: Schizophrenia trials
The registry lists 15 Schizophrenia studies with China Medical University Hospital as lead sponsor. 8 are open to participants now and 0 have results posted.
Phase 2 14No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Sex Differences in NMDA-enhancing Treatment of SchizophreniaRecruitingNCT07122895Phase 2
- Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of SchizophreniaRecruitingNCT06574360Phase 2
- NMDA-enhancing Treatment for Cognitive Dysfunction of SchizophreniaRecruitingNCT06021197Phase 2
- Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant SchizophreniaRecruitingNCT05240976Phase 2
- Early Intervention of Prodromal Schizophrenia Using an NMDA EnhancerRecruitingNCT05052853Phase 2
- Combination of NMDA-enhancing and Antioxidant Treatments for SchizophreniaRecruitingNCT04959201Phase 2
- Combination of NMDA-enhancing and Anti-inflammatory Treatments for SchizophreniaRecruitingNCT04917302Phase 2
- Monotherapy of an NMDA Enhancer for SchizophreniaRecruitingNCT04745143Phase 2
- DAAOI-2 add-on Treatment for Treatment-resistant SchizophreniaCompletedNCT02532686Phase 2
- DAAOI-1 Treatment for Treatment-resistant SchizophreniaCompletedNCT01390376Phase 2
- GlyT-1 Inhibitor Treatment for Refractory SchizophreniaCompletedNCT01251055Phase 2
- Expanding Rapid Ascertainment Network of Schizophrenia Families in TaiwanStatus unknownNCT01249079
- D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic SchizophreniaCompletedNCT00960219Phase 2
- Sarcosine or D-Serine Add-on Treatment for Chronic SchizophreniaCompletedNCT00491569Phase 2
- Sarcosine (N-Methylglycine) Monotherapy for SchizophreniaCompletedNCT00328276Phase 2